Immunogen Inc. | Mutual Funds
Mutual Funds that own Immunogen Inc.
American Funds Small Cap World Fund
7,433,000
4.99%
7,433,000
0.2%
06/30/2018
SPDR S&P Biotech ETF
6,984,140
4.69%
17,967
1.22%
09/06/2018
Fidelity Select Biotechnology Portfolio
5,221,673
3.5%
-170,700
0.57%
07/31/2018
Vanguard Total Stock Market Index Fund
3,661,203
2.46%
0
0.01%
07/31/2018
iShares Russell 2000 ETF
2,682,012
1.8%
-1,431
0.06%
09/06/2018
PRIMECAP Odyssey Growth Fund
2,400,000
1.61%
0
0.18%
06/30/2018
Vanguard Extended Market Index Fund
1,942,570
1.3%
7,500
0.03%
07/31/2018
iShares Nasdaq Biotechnology ETF
1,724,535
1.15%
-22,554
0.18%
09/06/2018
iShares Russell 2000 Growth ETF
1,269,104
0.85%
0
0.11%
09/06/2018
Delaware Healthcare Fund
1,130,000
0.76%
0
1.76%
03/31/2018
| Address |
830 Winter Street
Waltham Massachusetts 02451
United States
|
|
Employees
|
- |
| Website |
http://www.immunogen.com |
| Updated |
07/08/2019 |
| ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779, and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA. |
